Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsAndrew Mark FEDORIW, Susan KORENCHUK, Helai MOHAMMAD, Christian S. SHERK
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of treating cancer in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and administering to the human a therapeutically effective amount of an ICOS (CD278), Inducible T-cell Costimulator) binding protein or antigen binding portion thereof.
Claims18
A method of treating cancer in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and administering to the human a therapeutically effective amount of an ICOS binding protein or antigen binding portion thereof.
A method of treating cancer in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and administering to the human a therapeutically effective amount of an ICOS binding protein or antigen binding fragment thereof, wherein the Type I PRMT inhibitor is Compound A:
- or a pharmaceutically acceptable salt thereof, and the ICOS binding fragment or antigen binding fragment thereof comprises one or more of:
- CDRH1 as set forth in SEQ ID NO:1;
- CDRH2 as set forth in SEQ ID NO:2;
- CDRH3 as set forth in SEQ ID NO:3;
- CDRL1 as set forth in SEQ ID NO:4;
- CDRL2 as set forth in SEQ ID NO:5 and/or CDRL3 as set forth in SEQ ID NO:6 or a direct equivalent of each CDR wherein a direct equivalent has no more than two amino acid substitutions in said CDR.
A method of treating cancer in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of Type I protein arginine methyltransferase (Type I PRMT) inhibitor and administering to the human a therapeutically effective amount of an ICOS binding protein or antigen binding fragment thereof, wherein the Type I PRMT inhibitor is Compound A:
- or a pharmaceutically acceptable salt thereof, and the ICOS binding protein or antigen binding portion thereof comprises a Vu domain comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:7 and/or a VL domain comprising an amino acid sequence at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:8 wherein said ICOS binding protein specifically binds to human ICOS.
13-24. (canceled)
29-30. (canceled)
Dependencies are inferred from the claim text.